Trial Profile
A study to evaluate the clinical response to Ofatumumab and depletion of circulating chronic lymphocytic leukaemia cells in relapsed/refractory patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Feb 2017
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 28 Feb 2017 New trial record